The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.
The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.
The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.
Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records
Best-corrected visual acuity between 20/70 and HM in at least one eye as tested with clinic-based visual acuity method
Reasonably fluent in English
Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
Current pregnancy as reported by patient
6
Trial groupsSee each trial group below.
Ray Therapeutics, Inc.
Lead sponsor
The Vision Research and Assessment Institute (VRAI)
Collaborator